vs
FrontView REIT, Inc.（FVR）与礼来（RNA）财务数据对比。点击上方公司名可切换其他公司
FrontView REIT, Inc.的季度营收约是礼来的1.5倍（$18.2M vs $12.5M），FrontView REIT, Inc.净利率更高（2.2% vs -1398.3%，领先1400.5%），礼来同比增速更快（434.0% vs 12.0%）
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，在18个国家设有办事处，产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立，品牌名即取自创始人姓名。
FVR vs RNA — 直观对比
营收规模更大
FVR
是对方的1.5倍
$12.5M
营收增速更快
RNA
高出422.1%
12.0%
净利率更高
FVR
高出1400.5%
-1398.3%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.2M | $12.5M |
| 净利润 | $400.0K | $-174.4M |
| 毛利率 | — | — |
| 营业利润率 | 24.9% | -1513.5% |
| 净利率 | 2.2% | -1398.3% |
| 营收同比 | 12.0% | 434.0% |
| 净利润同比 | — | -117.0% |
| 每股收益（稀释后） | — | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRRNA
| Q1 26 | $18.2M | — | ||
| Q4 25 | $16.5M | — | ||
| Q3 25 | $16.8M | $12.5M | ||
| Q2 25 | $17.6M | $3.8M | ||
| Q1 25 | $16.2M | $1.6M | ||
| Q4 24 | — | $3.0M | ||
| Q3 24 | $14.5M | $2.3M | ||
| Q2 24 | — | $2.0M |
净利润FVRRNA
| Q1 26 | $400.0K | — | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | $-174.4M | ||
| Q2 25 | $-2.9M | $-157.3M | ||
| Q1 25 | $-833.0K | $-115.8M | ||
| Q4 24 | — | $-102.3M | ||
| Q3 24 | $-2.4M | $-80.4M | ||
| Q2 24 | — | $-70.8M |
营业利润率FVRRNA
| Q1 26 | 24.9% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -1513.5% | ||
| Q2 25 | — | -4448.7% | ||
| Q1 25 | — | -8360.9% | ||
| Q4 24 | — | -4069.6% | ||
| Q3 24 | — | -4200.9% | ||
| Q2 24 | — | -4040.4% |
净利率FVRRNA
| Q1 26 | 2.2% | — | ||
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | -1398.3% | ||
| Q2 25 | -16.5% | -4089.3% | ||
| Q1 25 | -5.1% | -7360.0% | ||
| Q4 24 | — | -3439.5% | ||
| Q3 24 | -16.7% | -3441.7% | ||
| Q2 24 | — | -3461.8% |
每股收益（稀释后）FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | $-1.27 | ||
| Q2 25 | $-0.16 | $-1.21 | ||
| Q1 25 | $-0.06 | $-0.90 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | — | $-0.65 | ||
| Q2 24 | — | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.3M | $350.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $514.2M | $1.9B |
| 总资产 | $869.8M | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FVRRNA
| Q1 26 | $9.3M | — | ||
| Q4 25 | $13.5M | — | ||
| Q3 25 | $19.6M | $350.2M | ||
| Q2 25 | $8.4M | $243.9M | ||
| Q1 25 | $3.3M | $254.2M | ||
| Q4 24 | — | $219.9M | ||
| Q3 24 | — | $370.2M | ||
| Q2 24 | — | $575.8M |
总债务FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益FVRRNA
| Q1 26 | $514.2M | — | ||
| Q4 25 | $391.2M | — | ||
| Q3 25 | $385.2M | $1.9B | ||
| Q2 25 | $369.9M | $1.2B | ||
| Q1 25 | $324.7M | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $1.0K | $1.5B | ||
| Q2 24 | — | $1.2B |
总资产FVRRNA
| Q1 26 | $869.8M | — | ||
| Q4 25 | $854.4M | — | ||
| Q3 25 | $846.8M | $2.1B | ||
| Q2 25 | $856.5M | $1.4B | ||
| Q1 25 | $860.8M | $1.5B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $1.0K | $1.6B | ||
| Q2 24 | — | $1.3B |
负债/权益比FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-156.9M |
| 自由现金流率自由现金流/营收 | — | -1257.6% |
| 资本支出强度资本支出/营收 | — | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-592.3M |
8季度趋势，按日历期对齐
经营现金流FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | — | ||
| Q3 25 | $8.3M | $-156.2M | ||
| Q2 25 | $9.3M | $-199.7M | ||
| Q1 25 | $8.1M | $-124.8M | ||
| Q4 24 | — | $-99.9M | ||
| Q3 24 | — | $-65.6M | ||
| Q2 24 | — | $-65.0M |
自由现金流FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-156.9M | ||
| Q2 25 | — | $-203.0M | ||
| Q1 25 | — | $-128.6M | ||
| Q4 24 | — | $-103.8M | ||
| Q3 24 | — | $-67.3M | ||
| Q2 24 | — | $-65.5M |
自由现金流率FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -1257.6% | ||
| Q2 25 | — | -5277.1% | ||
| Q1 25 | — | -8174.3% | ||
| Q4 24 | — | -3491.0% | ||
| Q3 24 | — | -2881.8% | ||
| Q2 24 | — | -3204.6% |
资本支出强度FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 86.9% | ||
| Q1 25 | — | 238.6% | ||
| Q4 24 | — | 131.7% | ||
| Q3 24 | — | 72.9% | ||
| Q2 24 | — | 26.0% |
现金转化率FVRRNA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
